# A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

Source: https://onco.cc/trials/nct06961006/  
OnCo record `nct06961006` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Intismeran autogene, Pembrolizumab in melanoma, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) is a phase 2 interventional study registered as NCT06961006 by Merck Sharp & Dohme LLC, with 160 participants planned, started 2025-05-29 and due to reach its primary completion in 2028-07-22. Interventions recorded: Intismeran autogene, Pembrolizumab, Placebo. Conditions listed: Malignant Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06961006
- Phase: 2
- Setting: A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With First-Line Advanced Melanoma (INTerpath-012)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 160

## Sources

- ClinicalTrials.gov NCT06961006: https://clinicaltrials.gov/study/NCT06961006

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Intismeran autogene](https://onco.cc/drugs/intismeran-autogene/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06961006.json